Salute e Benessere
Enea TECH and Biomedical Foundation invests €15 million in Tethis to develop new diagnostic methods in oncology using liquid biopsy
This platform makes it possible to characterize both immune cells and any circulating tumor cells, and to integrate cellular analysis with molecular markers present in plasma. The goal is to support accurate tumor diagnosis, monitor disease during and after treatment, and hopefully detect tumors early.
says Holger Neecke , CEO of Tethis.
underlines Maria Cristina Porta , General Manager of ENEA Tech and Biomedical Foundation.
This new funding round follows previous investments from Genextra and Indaco Venture Partners – the latter through the Atlante Ventures, Indaco Ventures I and Indaco Ventures I - Parallel Lombardia funds – which have supported the development of the Tethis platform until today.
SmartBioSurface slides are treated with biocompatible nanomaterials that enable spontaneous and efficient adhesion of typically non-adherent cells to perform in situ analysis of proteins, RNA, and DNA at the single cell level. The slides support simultaneous and sequential analyses ensuring the integrity of the cytology sample (multiplexing and multimodal), allow maintenance of cell morphology, and facilitate artificial intelligence-based imaging for detection and characterization of rare cancer and immune cells.
See.d is the first automated pre-analytical blood sample preparation tool for liquid biopsy to be performed at the point of collection to ensure sample integrity and clinical validity. It stabilizes the cellular fraction on SmartBioSurface slides for analysis of immune and tumor cells, while plasma is made available for identification of molecular analytes released from the tumor, including DNA, RNA, proteins, metabolites and exosomes.
The See.d instrument and SmartBioSurface slides are for research use only and are not intended for use in diagnostic procedures.
More information can be found at www.tethis-lab.com.
Logo: https://mma.prnewswire.com/media/2376704/4887129/Tethis_Logo.jpg
Logo: https://mma.prnewswire.com/media/2593755/Enea_TECH_Logo.jpg
media@tethis-lab.com
View original content:https://www.prnewswire.co.uk/news-releases/enea-tech-and-biomedical-foundation-invests-15-million-in-tethis-to-develop-new-diagnostic-methods-in-oncology-using-liquid-biopsy-302349579.html